How much has Alnylam Pharmaceuticals raised?
Alnylam Pharmaceuticals is not venture-backed. As of June 2026 it was a public company trading as Nasdaq: ALNY, with $2.987B 2025 net product revenue of 2025 revenue scale and mature access to public-company financing tools.
- Public status
- Nasdaq: ALNY
- Revenue
- $2.987B 2025 net product revenue
- Funding type
- Public markets
- Disclosed rounds
- Not VC disclosed
- First raised
- Public-company history
- Seller signal
- Enterprise healthcare buyer
Alnylam Pharmaceuticals's capital history
Alnylam Pharmaceuticals's capital history is public-company funding, operating cash flow, acquisitions, and market access rather than startup rounds.
- 2002Company foundedAlnylam Pharmaceuticals begins the business that later scales into a public healthcare company.
- Public listingNasdaq: ALNY public-market accessPublic equity and debt-market access replace startup-style venture rounds as the relevant capital lens.
- Portfolio eraPortfolio expansionAcquisitions, divestitures, internal R&D, and manufacturing investments become important capital-allocation tools.
- 2025$2.987B 2025 net product revenue revenue scaleAlnylam reported 2025 global net product revenues of $2.987 billion, up 81% from 2024, and achieved GAAP and non-GAAP profitability for the year.
- Jun 2026Nasdaq: ALNY public companyAlnylam Pharmaceuticals remains a public enterprise healthcare buyer with mature procurement controls.
Sources:Alnylam Pharmaceuticals annual reportsNasdaq: ALNY market data
How much has Alnylam Pharmaceuticals raised in total?
Alnylam Pharmaceuticals does not have a meaningful current venture-funding total. The company should be evaluated through public equity, operating cash flow, debt capacity, acquisitions, divestitures, partnerships, and retained earnings rather than Seed, Series A, or late-stage venture rounds.
Who are Alnylam Pharmaceuticals's investors?
The relevant investors are public-market shareholders, index funds, active healthcare investors, bondholders where applicable, and internal capital allocators. Their focus is durable revenue, margins, cash conversion, pipeline or product execution, regulatory risk, reimbursement exposure, and management's ability to deploy capital at attractive returns.
Why does Alnylam Pharmaceuticals's valuation move?
Alnylam Pharmaceuticals's valuation moves with growth, margins, cash flow, clinical or regulatory milestones, procedure or prescription trends, test volume, reimbursement, pricing pressure, product cycles, supply reliability, litigation, acquisitions, and investor confidence in management's outlook. Healthcare buyers can still spend during turbulent markets, but approvals become more tied to measurable savings and risk control.
Is Alnylam Pharmaceuticals profitable, and will it IPO?
Alnylam Pharmaceuticals is already public. Profitability should be assessed from its filings and earnings releases rather than IPO readiness; the practical question is how much cash and management attention can be allocated to new vendors, systems, facilities, clinical programs, commercial expansion, or productivity work.
What does Alnylam Pharmaceuticals's funding mean if you sell into them?
The company has enterprise-scale budget capacity, but procurement is mature and evidence-driven. Sellers should expect security review, compliance review, legal negotiation, business-unit sponsorship, and a requirement to prove value in patient outcomes, operating efficiency, revenue capture, supply reliability, cybersecurity, data quality, or risk reduction.
As of June 2026.Sources:Alnylam Pharmaceuticals 2025 resultsAlnylam Pharmaceuticals annual reportsNasdaq: ALNY market data
Alnylam Pharmaceuticals — frequently asked questions
